Cleary Gottlieb Steen & Hamilton and Li & Partners are acting for Jiangsu, China-based Hansoh Pharmaceutical Group, on its $1 billion Hong Kong initial public offering, with Clifford Chance and Tian Yuan Law Firm advising the joint sponsors and the underwriters.
Hansoh’s drug portfolio includes central nervous system diseases, oncology, anti-infectives, diabetes, gastrointestinal and cardiovascular therapies. The six therapeutic areas accounted for 62.5 percent of the pharmaceutical market in China in 2018, according to its prospectus.
The Cleary team was led by Hong Kong partner Freeman Chan, with support from Hong Kong partner Shuang Zhao, while Li & Partners’ Shenzhen office advised on PRC law.
The Clifford Chance cross-border team was led by partner Amy Lo, with China Co-Managing Partner Tim Wang and Shanghai-based partner Jean Thio, and Hong Kong-based parnters Fang Liu and Christine Xu, while the Tian Yuan team was led by partner Fu Siqi.
The Maples and Calder team advising the issuer on Cayman Islands law was led by parnter Derrick Kan.
佳利、高伟绅等共同助力翰森制药香港主板上市 融资逾10亿美元
美国佳利律师事务所和李伟斌律师事务所代表翰森制药集团有限公司（“翰森制药”）成功在香港联交所主板挂牌上市，全球发售融资额逾10亿美元，高伟绅律师事务所和天元律师事务所为联席保荐人和承销商提供法律服务。
翰森制药专注于中枢神经系统药物市场、抗肿瘤药物市场、抗感染药物市场、糖尿病及消化道药物市场、心血管治疗药物市场。据招股书显示，这六个治疗领域占2018年中国医药市场总销售额的62.5%。
佳利团队由香港合伙人Freeman Chan主导，香港合伙人Shuang Zhao提供大力支持，李伟斌律师事务所深圳办公室在本次交易中担任中国法的法律顾问。
高伟绅团队由香港办公室合伙人罗秀娴律师领导跨境团队，其中包括中国区联席管理合伙人王彦峰律师、上海办公室合伙人张珮真律师，以及香港办公室方刘律师和许文嘉律师。天元团队由合伙人傅思齐律师主导。
迈普达律师事务所在此次交易中为发行人提供开曼群岛法律服务，由合伙人简立基律师主导。
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
